LFMDNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as LFMDP
LifeMD, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$2.25−0.09 (-3.85%)
Close on Oct 19, 2026
- Market cap
- $107.52M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
85.7%+9.5 pts over 5 years
Operating margin
-4.0%+151.1 pts over 5 years
Net margin
7.4%+164.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +25.3% | +17.7% | +39.1% | +66.0% | |
| Gross profit | +24.7% | +18.3% | +42.4% | +67.3% | |
| Free cash flow | -60.1% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 868.3% | 3565.1% | 204.0% | |
| Return on assets | -178.9% | -696.1% | 19.6% | |
| Current ratio | 0.69 | 0.89 | 1.25 | |
| Debt to equity | – | – | – | |
| Interest coverage | -24.2× | -34.7× | -5.6× | |
| Inventory turnover | 17.6× | 8.0× | 9.9× | |
| Capex to revenue | – | – | 1.0% | |
| Diluted shares | 7M | 14M | 45M |
Where the cash went
Fiscal 2021 to 2025, five years combined
LifeMD generated $90.63M from operations and spent $17.72M on capital expenditure, dividends and share buybacks. 23% of that went back into the business.
Generated
$90.63M
Used
$17.72M
Capital expenditure$4.15M23%Dividends$13.30M75%Share buybacks$270.00K2%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin7.4%
×Asset turnover2.65×
×Equity multiplier10.41×
=Return on equity, FY2025204.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 7.4% | 2.65× | 10.41× | 204.0% |
| FY2024 | -13.8% | 2.30× | -24.13× | 767.6% |
| FY2023 | -13.5% | 3.63× | -10.66× | 522.1% |
| FY2022 | -38.3% | 3.15× | 6.66× | -802.8% |
| FY2021 | -65.6% | 2.93× | 3.10× | -595.9% |
| FY2020 | -157.3% | 4.43× | -5.12× | 3565.1% |
| FY2019 | -25.2% | 4.11× | -67.00× | 6934.2% |
| FY2018 | -14.9% | 4.29× | 2.18× | -139.4% |
| FY2017 | -32.8% | 3.59× | 3.90× | -457.9% |
| FY2016 | -21.1% | 8.46× | -4.85× | 868.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$14.35M
- Cash generatingOperating cash flow above zero$8.28M
- Return on assets improvedROA up on the prior year-36.6% → 18.9%
- Earnings backed by cashOperating cash flow above net income$8.28M vs $14.35M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.78 → 1.25
- No dilutionShare count did not rise41M → 45M
- Gross margin improvedGross margin up on the prior year86.15% → 85.72%
- More efficientAsset turnover rose2.65 → 2.55